Improving Antiretroviral Management for HIV
Improving Antiretroviral Management for HIV
批准号:
7578888
负责人:
RICHARD H HAUBRICH
金额:
$16.94万
依托单位国家:
美国
项目类别:
财政年份:
2006
资助国家:
美国
项目状态:
已结题
起止时间:
2006-03-15 至 2011-02-28
关键词:
AIDS clinical trial groupAnti-Retroviral AgentsCaliforniaClinicClinicalClinical ManagementClinical ResearchClinical TrialsClinical Trials DesignCollaborationsCommunicable DiseasesDevelopmentDrug KineticsDrug MonitoringEvaluationFacultyFailureFosteringFundingGeneticGenetic Crossing OverGenetic PolymorphismGenetic VariationGoalsHIVLopinavirMaster of Public HealthMentorsNucleosidesOutcomePathogenesisPathway interactionsPatientsPrincipal InvestigatorRandomized Controlled TrialsResearchResearch PersonnelResearch Project GrantsRoleStudentsTherapeuticTrainingViralantiretroviral therapybasedesigngraduate studentimprovedinsightpatient oriented researchresponsetreatment response
中文摘要
该项目的目标是对感染艾滋病毒的患者进行高质量的以患者为导向的研究
重点回答关于抗逆转录病毒治疗和基于临床和发病机制的问题
评估改善抗逆转录病毒治疗临床管理的新战略和新兴战略。这个
该项目的中心假设是,仔细规划和分析的研究不仅可以回答
关于具体治疗组合的问题,但也可以提供对
治疗反应和确定在诊所管理病人的策略。指导年轻的调查人员
(M.P.H.学生、传染病研究员和初级教员)将是该项目的中心目标。这些
目标将通过构思、设计、发起、实施和分析随机化来实现
与当地(UCSD AVRC)、全州(加州合作治疗)合作的对照试验
组[CCTG])和国家(艾滋病临床试验组[ACTG])临床试验组织。作为一个整体
CCTG首席调查员,我将能够延续促进
初级调查人员通过积极参与CCTG研究。主要的研究主题是
了解抗逆转录病毒暴露-反应关系及其对发病机制和
艾滋病毒的管理。具体目标是:
1)通过评价TDF+ABC治疗失败的机制,探讨TDF+ABC治疗失败的机制
核苷血浆和细胞内暴露-反应关系。这项研究将使用一种独特的临床
试验设计(交叉试验、短期病毒动力学药代动力学评价)以评估相互作用
在TDF和ABC之间。
2)明确抗逆转录病毒暴露-反应关系在艾滋病毒治疗中的作用。目标2 A:达到
评价治疗药物监测(TDM)对改善心力衰竭的管理和预后的价值
抗逆转录病毒治疗。目标2B:定义遗传差异(由等位基因变异定义)的影响
单核苷酸多态)与抗逆转录病毒药物洛匹那韦的暴露和反应有关。
英文摘要
The goal of this project is to conduct high quality patient oriented research with HIV infected patients which
focuses on answering clinical and pathogenesis based questions concerning antiretroviral therapy and
evaluates new and emerging strategies to improve the clinical management of antiretroviral therapy. The
central hypothesis of the project is that carefully planned and analyzed studies can not only answer
questions about specific treatment combinations, but can also provide insight into the pathogenesis of
treatment responses and define strategies to manage patients in the clinic. Mentoring young investigators
(M.P.H. students, Infectious Disease fellows, and junior faculty) will be a central goal of this project. These
goals will be accomplished by conceiving, designing, initiating, carrying out, and analyzing randomized
controlled trials in collaboration with local (UCSD AVRC), statewide (California Collaborative Treatment
Group [CCTG]), and national (AIDS Clinical Trials Group [ACTG]) clinical trials organizations. As the overall
Principal Investigator of the CCTG, I will be able to continue the tradition of fostering the development of
junior investigators through active participation in CCTG studies. The primary research theme is to
understand the antiretroviral exposure-response relationship and its implications for the pathogenesis and
management of HIV. The specific aims are:
1) To examine the mechanistic pathways leading to therapeutic failure of TDF + ABC by evaluating
nucleoside plasma and intracellular exposure-response relationships. The study will use a unique clinical
trial design (cross-over, pharmacokinetic evaluation of short-term viral dynamics) to evaluate the interaction
between TDF and ABC.
2) To define the role of antiretroviral exposure-response relationships in HIV therapeutics. Aim 2A: To
evaluate the value of therapeutic drug monitoring (TDM) to improve the management and outcome of
antiretroviral therapy. Aim 2B: To define the impact of genetic differences (defined by allelic variants of
single nucleoside polymorphisms) on exposure and response to lopinavir, the antiretroviral agent.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Screening for atherosclerotic vascular disease in HIV-infected children
-
批准号:8839837
-
项目类别:
-
资助金额:$34.45万
-
财政年份:2015
-
负责人:RICHARD H HAUBRICH
-
依托单位:
Assessing the Clinical Consequences of HIV Drug Resistance
-
批准号:7555003
-
项目类别:
-
资助金额:$19.31万
-
财政年份:2008
-
负责人:RICHARD H HAUBRICH
-
依托单位:
Assessing the Clinical Consequences of HIV Drug Resistance
-
批准号:7690947
-
项目类别:
-
资助金额:$23.18万
-
财政年份:2008
-
负责人:RICHARD H HAUBRICH
-
依托单位:
Clinical Investigation
-
批准号:7635789
-
项目类别:
-
资助金额:$22.42万
-
财政年份:2008
-
负责人:RICHARD H HAUBRICH
-
依托单位:
Clinical Investigation
-
批准号:7278950
-
项目类别:
-
资助金额:$23.3万
-
财政年份:2007
-
负责人:RICHARD H HAUBRICH
-
依托单位:
Improving Antiretroviral Management for HIV
-
批准号:8848023
-
项目类别:
-
资助金额:$19.31万
-
财政年份:2006
-
负责人:RICHARD H HAUBRICH
-
依托单位:
Improving Antiretroviral Management for HIV
-
批准号:7064358
-
项目类别:
-
资助金额:$15.48万
-
财政年份:2006
-
负责人:RICHARD H HAUBRICH
-
依托单位:
ACTG A5142 LOPINAVIR/RITONAVIR PLUS EFAVIRENZ FOR HIV-1 INFECTION
-
批准号:7374177
-
项目类别:
-
资助金额:$1.17万
-
财政年份:2006
-
负责人:RICHARD H HAUBRICH
-
依托单位:
Improving Antiretroviral Management for HIV
-
批准号:8140837
-
项目类别:
-
资助金额:$19.31万
-
财政年份:2006
-
负责人:RICHARD H HAUBRICH
-
依托单位:
Improving Antiretroviral Management for HIV
-
批准号:8423355
-
项目类别:
-
资助金额:$19.31万
-
财政年份:2006
-
负责人:RICHARD H HAUBRICH
-
依托单位:
Improving Antiretroviral Management for HIV
-
批准号:8623093
-
项目类别:
-
资助金额:$19.31万
-
财政年份:2006
-
负责人:RICHARD H HAUBRICH
-
依托单位:
Improving Antiretroviral Management for HIV
-
批准号:7380061
-
项目类别:
-
资助金额:$16.1万
-
财政年份:2006
-
负责人:RICHARD H HAUBRICH
-
依托单位:
Improving Antiretroviral Management for HIV
-
批准号:8225166
-
项目类别:
-
资助金额:$19.31万
-
财政年份:2006
-
负责人:RICHARD H HAUBRICH
-
依托单位:
ACTG A5142 LOPINAVIR/RITONAVIR PLUS EFAVIRENZ FOR HIV -1 INFECTION
-
批准号:7606527
-
项目类别:
-
资助金额:$0.33万
-
财政年份:2006
-
负责人:RICHARD H HAUBRICH
-
依托单位:
Improving Antiretroviral Management for HIV
-
批准号:7195818
-
项目类别:
-
资助金额:$15.97万
-
财政年份:2006
-
负责人:RICHARD H HAUBRICH
-
依托单位:
ACTG A5079 PHYSIOLOGIC TESTOSTERONE SUPPLEMENTATION IN HIV
-
批准号:7374162
-
项目类别:
-
资助金额:$0.39万
-
财政年份:2006
-
负责人:RICHARD H HAUBRICH
-
依托单位:
ACTG A5142 LOPINAVIR/RITONAVIR PLUS EFAVIRENZ FOR HIV-1 INFECTION
-
批准号:7045466
-
项目类别:
-
资助金额:$0.44万
-
财政年份:2003
-
负责人:RICHARD H HAUBRICH
-
依托单位:
ACTG A5079 PHYSIOLOGIC TESTOSTERONE SUPPLEMENTATION IN HIV
-
批准号:7205600
-
项目类别:
-
资助金额:$1.17万
-
财政年份:2003
-
负责人:RICHARD H HAUBRICH
-
依托单位:
ACTG A5142 LOPINAVIR/RITONAVIR PLUS EFAVIRENZ FOR HIV-1 INFECTION
-
批准号:7205632
-
项目类别:
-
资助金额:$1.33万
-
财政年份:2003
-
负责人:RICHARD H HAUBRICH
-
依托单位:
ACTG A5079 Physiologic Testosterone Supplements in HIV
-
批准号:7045423
-
项目类别:
-
资助金额:$1.82万
-
财政年份:2003
-
负责人:RICHARD H HAUBRICH
-
依托单位:
海外基金